Thought Leadership
Recovering A Clinical Trial That Has Been Derailed
When your asset is on the line, your partner of choice matters […]
Read More....High-Velocity Development: Gene Therapy Vs. Small Molecule
Gene therapy development operates at a high velocity compared to small molecule […]
Read More....Rare Disease Clinical Endpoints: Ingenuity Meets Practicality
Discover why the science that brought you to this point can only […]
Read More....CRAs Must Evolve Alongside Oncology Therapeutics
Clinical Research Associates (CRAs) must adapt to the evolving demands of oncology […]
Read More....FDA Update on ICH E6, E8, QbD and RBM in Clinical Trials
Integrating Quality by Design (QbD) and Risk-Based Monitoring (RBM) approaches in clinical […]
Read More....Revolutionizing Clinical Trials: The Power And Potential Of Risk-Based Monitoring
The article explores the benefits and misconceptions of risk-based monitoring (RBM) in […]
Read More....How Sponsors and Patients Benefit From a Site-Centric Partnership
Site-centric partnerships between sponsors and clinical trial sites can significantly enhance patient […]
Read More....Is A Multitherapeutic Contract Research Partner The Best Fit For Your Clinical Trial?
Evaluating the suitability of multitherapeutic contract research organizations (CROs) for clinical trials […]
Read More....Successful Regulatory Submission Via the Trifecta of Awesomeness
The article discusses the key elements that lead to a successful regulatory […]
Read More....Why the Regional Site Manager Is the Swiss Army Knife of Clinical Trial Monitoring
The Regional Site Manager (RSM) monitoring model enhances clinical trial oversight by […]
Read More....